SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review

AIM OF THE STUDY: To evaluate the efficacy of sodium/glucose cotransporter-2 inhibitors (SGLT2i) in improving hepatic fibrosis and steatosis of non-alcoholic fatty liver disease (NAFLD) patients with type 2 diabetes mellitus (T2DM). MATERIAL AND METHODS: We searched CENTRAL, MEDLINE, and EMBASE and...

Descripción completa

Detalles Bibliográficos
Autores principales: Dwinata, Michael, Putera, David Dwi, Hasan, Irsan, Raharjo, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2020
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816633/
https://www.ncbi.nlm.nih.gov/pubmed/33511282
http://dx.doi.org/10.5114/ceh.2020.102173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816633/
https://www.ncbi.nlm.nih.gov/pubmed/33511282
http://dx.doi.org/10.5114/ceh.2020.102173

Ejemplares similares